• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The era of combination of nephroprotective agents in CKD is there.

作者信息

Jadoul Michel, Rossing Peter

机构信息

Cliniques universitaires Saint-Luc, Université Catholique de Louvain - Department of Nephrology, 1200 Brussels, Belgium.

Steno Diabetes Center Copenhagen, 2730 Herlev, Denmark.

出版信息

Nephrol Dial Transplant. 2025 Feb 5;40(Supplement_1):i1-i2. doi: 10.1093/ndt/gfae260.

DOI:10.1093/ndt/gfae260
PMID:39907537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11795657/
Abstract
摘要

相似文献

1
The era of combination of nephroprotective agents in CKD is there.慢性肾脏病中肾保护药物联合应用的时代已经到来。
Nephrol Dial Transplant. 2025 Feb 5;40(Supplement_1):i1-i2. doi: 10.1093/ndt/gfae260.
2
Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease-Clinical Practice Position Statement of the Polish Society of Nephrology.非糖尿病慢性肾脏病的药物性肾保护——波兰肾脏病学会临床实践立场声明
J Clin Med. 2023 Aug 9;12(16):5184. doi: 10.3390/jcm12165184.
3
Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.甲氧基聚乙二醇-促红细胞生成素β作为一种新型促红细胞生成刺激剂，对非透析慢性肾脏病患者可能具有肾脏保护和心血管保护作用。
Curr Pharm Biotechnol. 2017;18(4):303-308. doi: 10.2174/1389201018666170127104801.
4
Maqui and Chronic Kidney Disease: A Narrative Review on the Potential Nephroprotective Role of Anthocyanins.马基莓与慢性肾脏病：关于花色苷潜在肾保护作用的叙述性综述
Nutrients. 2025 Mar 18;17(6):1058. doi: 10.3390/nu17061058.
5
Nephroprotective Properties of Antidiabetic Drugs.抗糖尿病药物的肾脏保护特性
J Clin Med. 2023 May 10;12(10):3377. doi: 10.3390/jcm12103377.
6
The Role of PGC-1α and Mitochondrial Biogenesis in Kidney Diseases.PGC-1α与线粒体生物合成在肾脏疾病中的作用
Biomolecules. 2020 Feb 24;10(2):347. doi: 10.3390/biom10020347.
7
Nephroprotective and nephrotoxic effects of Rhubarb and their molecular mechanisms.大黄的肾保护和肾毒性作用及其分子机制。
Biomed Pharmacother. 2023 Apr;160:114297. doi: 10.1016/j.biopha.2023.114297. Epub 2023 Jan 28.
8
Nephroprotective effect of pioglitazone in a Wistar rat model of adenine‑induced chronic kidney disease.吡格列酮对腺嘌呤诱导的Wistar大鼠慢性肾病模型的肾保护作用
Exp Ther Med. 2024 Aug 7;28(4):392. doi: 10.3892/etm.2024.12681. eCollection 2024 Oct.
9
Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease.选择性内皮素 A 受体拮抗剂治疗蛋白尿性慢性肾脏病患者。
Expert Opin Investig Drugs. 2021 Mar;30(3):253-262. doi: 10.1080/13543784.2021.1869720. Epub 2020 Dec 30.
10
Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.血脂异常、他汀类药物和 CKD 患者的结局 - 后 sharp 时代的证据回顾。
J Nephrol. 2012 Jul-Aug;25(4):460-72. doi: 10.5301/jn.5000154.

本文引用的文献

1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
2
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.KDIGO 2024慢性肾脏病评估与管理临床实践指南
Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.
3
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.醛固酮合酶抑制联合和不联合恩格列净治疗慢性肾脏病的疗效和安全性：一项随机、对照、2 期临床试验。
Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15.
4
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.西他列汀联合达格列净对比达格列净治疗慢性肾脏病患者（ZENITH-CKD）：一项多中心、随机、阳性对照、2b 期临床试验。
Lancet. 2023 Nov 25;402(10416):2004-2017. doi: 10.1016/S0140-6736(23)02230-4. Epub 2023 Nov 3.
5
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression.糖尿病肾病：治疗进展减缓支柱的最新进展。
Diabetes Care. 2023 Sep 1;46(9):1574-1586. doi: 10.2337/dci23-0030.
6
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.KDIGO 2022慢性肾脏病糖尿病管理临床实践指南
Kidney Int. 2022 Nov;102(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008.
7
Combined angiotensin inhibition for the treatment of diabetic nephropathy.联合应用血管紧张素抑制剂治疗糖尿病肾病。
N Engl J Med. 2013 Nov 14;369(20):1892-903. doi: 10.1056/NEJMoa1303154. Epub 2013 Nov 9.
8
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.阿利克仑治疗 2 型糖尿病的心血管和肾脏终点试验。
N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.
9
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.替米沙坦、雷米普利或二者联用对高血管风险人群的肾脏结局影响（ONTARGET研究）：一项多中心、随机、双盲、对照试验
Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2.
10
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.氯沙坦对2型糖尿病肾病患者肾脏和心血管结局的影响。
N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161.